Country: Canada
Language: English
Source: Health Canada
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
APOTEX INC
A10BD15
METFORMIN AND DAPAGLIFLOZIN
5MG; 850MG
TABLET
DAPAGLIFLOZIN 5MG; METFORMIN HYDROCHLORIDE 850MG
ORAL
15G/50G
Prescription
Active ingredient group (AIG) number: 0257650001; AHFS:
APPROVED
2023-05-16
_APO-DAPAGLIFLOZIN-METFORMIN (dapagliflozin and metformin hydrochloride tablets) _ _Page 1 of 85 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR APO-DAPAGLIFLOZIN-METFORMIN Dapagliflozin and Metformin Hydrochloride tablets Tablets, 5 mg dapagliflozin / 850 mg metformin hydrochloride, 5 mg dapagliflozin / 1000 mg metformin hydrochloride, for oral use Combination of oral blood glucose lowering drugs Apotex Inc. 150 Signet Drive Toronto, Ontario M9L 1T9 Date of Initial Authorization: MAY 16, 2023 Date of Revision: SEP 19, 2023 Submission Control Number: 275438 _APO-DAPAGLIFLOZIN-METFORMIN (dapagliflozin and metformin hydrochloride tablets) _ _Page 2 of 85 _ RECENT MAJOR LABEL CHANGES 1. INDICATIONS. 1.2 Geriatrics 09/2023 2 CONTRAINDICATIONS 09/2023 4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations 09/2023 4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage Adjustment 09/2023 4 DOSAGE AND ADMINISTRATION, 4.4 Administration 09/2023 7 WARNINGS AND PRECAUTIONS, Driving and Operating Machinery 09/2023 7 WARNINGS AND PRECAUTIONS, Endocrine and Metabolism 09/2023 7 WARNINGS AND PRECAUTIONS, Hematologic 09/2023 7 WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic 09/2023 7 WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests 09/2023 7 WARNINGS AND PRECAUTIONS, Neurologic 09/2023 7 WARNINGS AND PRECAUTIONS, Renal 09/2023 7.1.4 Geriatrics 09/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 5 1 INDICATIONS ................................................................................................................ 5 1.1 Pediatrics .................................... Read the complete document